Vaccines in older age: moving from current practice to optimal coverage—a multidisciplinary consensus conference
- 22 June 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in Aging Clinical and Experimental Research
- Vol. 32 (8), 1405-1415
- https://doi.org/10.1007/s40520-020-01622-z
Abstract
Vaccines are a key strategy to promote healthy aging, but vaccine coverage remains below target levels in at-risk adults and older individuals. We present here the results of a multidisciplinary consensus conference convened to perform a multidimensional assessment of vaccination in geriatric medicine, with a view to developing a well-defined strategy for the promotion of vaccines in older people. We discuss recommended vaccines in older individuals, and describe the wide regional heterogeneity between regions in the Italian context. The main obstacles to implementation of vaccines in practice are reviewed, as well as potential strategies to remove these barriers. Finally, the importance of including vaccines and vaccination in undergraduate and postgraduate medical education is underlined. The information summarized in this document is expected to help develop educational and promotional initiatives to achieve greater uptake of vaccines among older individuals, as a key means to promote healthy aging.Keywords
Funding Information
- MSD Italia Srl
This publication has 31 references indexed in Scilit:
- Efficacy of an Adjuvanted Herpes Zoster Subunit Vaccine in Older AdultsThe New England Journal of Medicine, 2015
- Systematic review of incidence and complications of herpes zoster: towards a global perspectiveBMJ Open, 2014
- Feature-tracking cardiovascular magnetic resonance as a novel technique for the assessment of mechanical dyssynchronyEuropean Heart Journal, 2013
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 70 years of age and older previously vaccinated with 23-valent pneumococcal polysaccharide vaccineVaccine, 2013
- Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine compared to a 23-valent pneumococcal polysaccharide vaccine in pneumococcal vaccine-naive adultsVaccine, 2013
- Influence of initial vaccination with 13-valent pneumococcal conjugate vaccine or 23-valent pneumococcal polysaccharide vaccine on anti-pneumococcal responses following subsequent pneumococcal vaccination in adults 50 years and olderVaccine, 2013
- Effectiveness of pneumococcal polysaccharide vaccine against pneumonia and cost analysis for the elderly who receive seasonal influenza vaccine in JapanVaccine, 2010
- Clinical and economic burden of community-acquired pneumonia among adults in EuropeThorax, 2010
- Immunogenicity and Reactogenicity of Pneumococcal Polysaccharide and Conjugate Vaccines in Alaska Native Adults 55–70 Years of AgeClinical Infectious Diseases, 2009
- Advocating Vaccination of Adults Aged 60 Years and Older in Western Europe:Rejuvenation Research, 2009